Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.
As date of Aug 30, 2023
Therapy | Indications | Phase I | Phase IIa | Phase IIb Pivotal | Recent progress |
---|---|---|---|---|---|
Mono | NSCLC |
|
Pivotal study enrollment to be completed Sep 2023 |
||
Mono | PDAC |
|
Pivotal study approved Jul 2023 BTD granted Aug 2023 |
||
Combo w/EGFR mAb | CRC |
|
Patient enrollment of Phase IIa completed Feb 2023 |
||
Combo w/SHP2i JAB-3312 | NSCLC, CRC and other solid tumors |
|
|||
Mono | 1L NSCLC with STK11 co-mutation |
|
|||
Combo w/PD-1 mAb | NSCLC |
|
|||
Mono |
NSCLC、PDAC、CRC and other solid tumors |
|
JAB-3068 is the second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).
Therapy | Indications | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|
KRAS G12Ci Combination Therapy | KRAS G12C mut NSCLC |
|
Phase IIa initiated Jul 2022 |
|
Combo w/EGFRi | Osimertinib progressed NSCLC |
|
FPI Jan 2022 |
|
Combo w/PD-1 mAb | NSCLC, HNSCC, ESCC |
|
Phase IIa FPI Feb 2022 |
KRASmulti inhibitor JAB-23425 targets multiple KRAS mutants in both RAS(ON) and RAS (OFF), with good selectivity over HRAS and NRAS.
Modality | Indications | Lead Optimization | IND-enabling | Recent Development | IND Schedule |
---|---|---|---|---|---|
Small molecule |
PDAC, CRC, NSCLC |
|
IND to be submitted in 2024 H1 |
2024 IND |
JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.
As date of Aug 30, 2023
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
FPI in U.S. The first site in China was initiated |
JAB-BX300 is Jacobio’s self-developed LIF mAb. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC). Studies show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improving therapeutic outcomes. LIF is an attractive target for the treatment of KRAS-driven tumors, which has potential to combo with KRAS and SHP2 inhibitors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Apr 2023 |
JAB-22000 is a small-molecule KRAS G12D inhibitor. Currently, there is only one small molecule KRAS G12D program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-22000 has the potential to be among the first few market entrants.
Modality | Indications | Lead Optimization | IND-enabling | Recent Development | IND Schedule |
---|---|---|---|---|---|
Small molecule |
PDAC, CRC, NSCLC |
|
IND schedule will be adjusted according to the progress and the clinical efficacy and safety data of JAB-23400, our KRASmulti inhibitor |
JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have n that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
RP2D to be determined in 2023H2 |
||
Monotherapy | Solid Tumor |
|
|||
Monotherapy | MF, AML |
|
JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Mar 2023 |
JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.
As date of Aug 30, 2023
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
FPI in U.S. The first site in China was initiated |
JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation.
Modality | Indications | Lead Optimization | IND-enabling | Recent Development | IND Schedule |
---|---|---|---|---|---|
Small molecule |
Solid tumors |
|
Candidate nominated, entering into IND enabling studies in Jul 2022 | 2023IND |
JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Mar 2023 |
JAB-X1800 is the world's first iADC by conjugating Jacobio’s STING agonist to CD73 antibody, which is expected to turn the tumor from "cold" to "hot".
As date of Aug 30, 2023
Modality | Indications | Lead Optimization | IND-enabling | Recent Development | IND Schedule |
---|---|---|---|---|---|
Small molecule |
Solid tumors |
|
Candidate nominated in 2023 Q1 |
2024-2025 IND |
Our HER2-STING iADC showed excellent features in pre-clinical studies, including favorable physicochemical properties at even high drug to antibody ratio value, hundreds to thousands fold improvement in activity over the free STING payload, and complete and durable tumor regression with only single dose in SK-OV-3 CDX model.
As date of Aug 30, 2023
Modality | Indications | Lead Optimization | IND-enabling | Recent Development | IND Schedule |
---|---|---|---|---|---|
Small molecule |
Solid tumors |
|
- |
2024-2025 IND |
JAB-BX300 is Jacobio’s self-developed PARP7 inhibitor. PARP7 inhibitors target I/O (immuno-oncology) signaling pathway and can be used to treat various solid tumors such as squamous NSCLC, and HNSCC. Studies show that, PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Jun 2023 |
JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.
As date of Aug 30, 2023
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Mono and Combo w/ PD-1 antibody | Solid Tumor |
|
RP2D to be determined in 2024 H1 |
Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer; KRAS amp = KRAS amplification; LOF = loss of function; CRC = colorectal cancer; MF = myelofibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; IND = investigational new drug.
As date of Jun 8, 2023